share_log

Boston Scientific | 8-K: Boston Scientific Announces Results for Third Quarter 2024

Boston Scientific | 8-K: Boston Scientific Announces Results for Third Quarter 2024

波士頓科學 | 8-K：波士頓科學公佈2024年第三季度業績
美股SEC公告 ·  2024/10/23 18:35

牛牛AI助理已提取核心訊息

Boston Scientific Corporation reported robust Q3 2024 financial results, with net sales of $4.209 billion, up 19.4% year-over-year. Organic revenue growth was 18.2%, exceeding guidance of 13-15%. GAAP EPS was $0.32, while adjusted EPS reached $0.63, surpassing the guidance range of $0.57-$0.59.The company saw strong performance across segments, with Cardiovascular sales up 25.0% and MedSurg sales increasing 10.3%. Geographically, U.S. sales grew 23.5%, while Emerging Markets rose 15.2%. Boston Scientific highlighted several regulatory approvals and product launches, including the FARAWAVE NAV Ablation Catheter and ACURATE Prime Aortic Valve System.For full-year 2024, Boston Scientific raised guidance, projecting approximately 16.5% reported net sales growth and 15% organic growth. The company expects GAAP EPS of $1.28-$1.30 and adjusted EPS of $2.45-$2.47. Q4 2024 organic revenue growth is forecast at 14-16%, with adjusted EPS of $0.64-$0.66.
Boston Scientific Corporation reported robust Q3 2024 financial results, with net sales of $4.209 billion, up 19.4% year-over-year. Organic revenue growth was 18.2%, exceeding guidance of 13-15%. GAAP EPS was $0.32, while adjusted EPS reached $0.63, surpassing the guidance range of $0.57-$0.59.The company saw strong performance across segments, with Cardiovascular sales up 25.0% and MedSurg sales increasing 10.3%. Geographically, U.S. sales grew 23.5%, while Emerging Markets rose 15.2%. Boston Scientific highlighted several regulatory approvals and product launches, including the FARAWAVE NAV Ablation Catheter and ACURATE Prime Aortic Valve System.For full-year 2024, Boston Scientific raised guidance, projecting approximately 16.5% reported net sales growth and 15% organic growth. The company expects GAAP EPS of $1.28-$1.30 and adjusted EPS of $2.45-$2.47. Q4 2024 organic revenue growth is forecast at 14-16%, with adjusted EPS of $0.64-$0.66.
波士頓科學公司公佈了2024年第三季度強勁的財務業績，淨銷售額爲42.09億美元，同比增長19.4%。有機營業收入增長爲18.2%，超過了指導範圍的13-15%。GAAP每股收益爲0.32美元，而調整後的每股收益達到0.63美元，超出指導區間的0.57-0.59美元。該公司在各個細分市場表現強勁，心血管產品銷售增長25.0%，外科銷售增長10.3%。在地理上，美國銷售增長23.5%，而新興市場上漲15.2%。波士頓科學強調了多個監管批准和產品發佈，包括FARAWAVE NAV消融導管和ACURATE Prime主動脈瓣系統。對於2024財年，波士頓科學上調了指導，預計報告淨銷售增長約爲16.5%和15%的有機增長。公司預計GAAP每股收益爲1.28-1.30美元，調整後的每股收益爲2.45-2.47美元。2024年第四季度的有機營業收入增長預測爲14-16%，調整後的每股收益爲0.64-0.66美元。
波士頓科學公司公佈了2024年第三季度強勁的財務業績，淨銷售額爲42.09億美元，同比增長19.4%。有機營業收入增長爲18.2%，超過了指導範圍的13-15%。GAAP每股收益爲0.32美元，而調整後的每股收益達到0.63美元，超出指導區間的0.57-0.59美元。該公司在各個細分市場表現強勁，心血管產品銷售增長25.0%，外科銷售增長10.3%。在地理上，美國銷售增長23.5%，而新興市場上漲15.2%。波士頓科學強調了多個監管批准和產品發佈，包括FARAWAVE NAV消融導管和ACURATE Prime主動脈瓣系統。對於2024財年，波士頓科學上調了指導，預計報告淨銷售增長約爲16.5%和15%的有機增長。公司預計GAAP每股收益爲1.28-1.30美元，調整後的每股收益爲2.45-2.47美元。2024年第四季度的有機營業收入增長預測爲14-16%，調整後的每股收益爲0.64-0.66美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間